Fig. 5: NK-cell depletion allows outgrowth of CDK8-deficient TNBC tumor cells.

A Experimental setup of data shown in (B, C). Rag2−/− mice were NK-cell depleted by i.p. injections of an αNK1.1 antibody (200 µg/mouse), three times prior to implantation of E0771 control or shCdk8-2 cells and subsequently twice per week. B Primary tumor growth of control vs. shCdk8-2 E0771 cells, of mice treated with αNK1.1 antibody (PBS injection served as control). Symbols and error bars represent tumor size (mm2) in mean ± SEM. C Tumor weight of mice at day 15 after tumor implantation at the endpoint of the experiment ±SEM (n = 4 mice per group).